Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

Pfizer to sell stake in GSK's consumer health business after it lists

Stock Markets Jun 01, 2022 11:01AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri/File Photo
 
CL
-5.22%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
-1.04%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
-0.39%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
UL
-0.60%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BAYRY
-0.07%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GLNCY
-0.66%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Natalie Grover and Ludwig Burger

LONDON (Reuters) -Pfizer plans to sell its 32% stake in Haleon, its consumer health venture with British drugmaker GSK, after the business lists as an independent company in July, GSK said on Wednesday.

GSK is spinning off Haleon, which makes Sensodyne toothpaste and Advil painkillers, so it can focus on vaccines and prescription drugs. GSK rejected a 50 billion pound ($63 billion) offer for Haleon last year, saying it undervalued the firm.

Pfizer (NYSE:PFE) has previously indicated it wanted to sell its stake in Haleon but GSK, which owns 68% of the world's biggest consumer health business, said in February that the U.S. drugmaker would keep its stake after a flotation.

A Pfizer spokesperson said on Wednesday that the U.S. company had always intended to sell its Haleon stake over time.

GSK has applied to Britain's regulator to list Haleon on the London Stock Exchange on July 18 and said it expected to apply to list it on the New York Stock Exchange as well soon.

Pfizer, GSK and other current Haleon stakeholders have committed to a lock-up period until November, so as not to jeopardise the stock of the new independent company, GSK said.

Expectations for the consumer healthcare venture's market valuation are high after GSK rejected the 50 billion pound offer from Unilever (NYSE:UL), which abandoned its pursuit in January.

If GSK secures valuation of 50 billion pounds or more it would be the largest listing by market capitalisation on the London Stock Exchange in at least two decades, excluding joint listings made via the Shanghai London Stock Connect project.

As a comparison, mining and commodity trading company Glencore (OTC:GLNCY) was valued at 36.7 billion pounds when it listed in London in 2011.

BOARD MEMBERS

GSK also said in February that once Haleon was listed as a separate company, Pfizer would appoint two members to its new board and the British drugmaker would relinquish its right to representation.

At the moment, Brian McNamara, chief executive of GSK consumer healthcare, has been designated as chief executive of Haleon once it has listed while GSK's Tobias Hestler is the designated chief financial officer.

The Pfizer spokesperson said the company was given the right to board seats when the venture was initially announced several years ago and, for now, Pfizer still had an interest in Haleon.

"We can't speculate on what happens when we divest our interest," the spokesperson said.

Haleon was poised to generate above market, medium-term annual organic revenue growth of 4% to 6%, GSK said.

Haleon's closest competitors in the non-prescription drugs, vitamins and oral care market are Procter and Gamble, Colgate-Palmolive (NYSE:CL), Johnson & Johnson (NYSE:JNJ) and Bayer (OTC:BAYRY).

Before the spinoff, the holding company for Haleon will pay dividends to GSK and Pfizer. GSK said it would receive cash proceeds of more than 7 billion pounds at separation.

After the spinoff, at least 54.5% of Haleon's total issued ordinary share capital would be held by GSK shareholders and 6% would be held by GSK, the company said.

Following the split, GSK will focus on pharmaceuticals and vaccines and can no longer rely on steady consumer health sales to offset some of the unpredictability of drug development.

Under pressure from shareholders such as activist investor Elliot, GSK has sought to shore up its drug pipeline.

It has also made acquisitions, agreeing to purchase cancer drug developer Sierra Oncology (NASDAQ:SRRA) in a $1.9 billion deal and unveiling plans to pay up to $3.3 billion for vaccine developer Affinivax.

($1 = 0.7933 pounds)

Pfizer to sell stake in GSK's consumer health business after it lists
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email